Co-Win Ventures
Founded in 2009, Co-Win Ventures focuses on early-stage original innovation-based enterprise investment in the sector of healthcare and technology with dual-currency RMB and US dollar. With total capital under management of over RMB 6 billion, Co-Win Ventures has provided capital and resource support to more than 130 outstanding startups. The company has built an extensive global network around innovative precision therapeutics.
Bolstering its investments by serving as an external partner to start-up teams for over 10 years, Co-Win Ventures accompany them to grow to mature stages by creating significant value-add, while jointly facilitating industrial progress and social development.
At present, more than 10 companies have been listed in capital market and more than 10 companies are planned to be listed. Co-win Ventures has full-cycle experience in enterprise management from starting up to successful listing.
HuntBest Capital
HuntBest Capital was founded in 2021 by a team with industry and investment experience. Now, we manage ~300M RMB and invest early-stage private companies in healthcare and renewable energy fields. Our goal is to help entrepreneurs turn their knowledge and creativity into successful companies with fundraising and post-investment management. We believe that pragmatic innovation makes great investment return.
Sangel Capital
Sangel Capital is one of the earliest established healthcare venture capital firms in China. Deliciated to novel technologies and healthcare innovation, the firm focuses on investing in startups in biotech, biopharma, medical devices, and digital health.
Sangel capital identifies particularly promising startups that can achieve high return, and helps the portfolio to grow to their full potential.
With headquarters in Shenzhen, Sangel Capital has offices in Beijing, Suzhou, and the US.
Shanghai Healthcare Capital
With the approval of the Shanghai municipal government, Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC) established Shanghai Healthcare Capital (SHC) with market-oriented, professional and international operation principles. The total fund scale of SHC reached 50 Bn RMB.
Welcome information
BioTroy Therapeutics is a biopharmaceutical company dedicated to the research and development of first-in-class therapies for the treatment of cancer and immunological disorders. We are very proud and excited by getting the opportunity to welcome domestic and international VCs as the new shareholder of our company. Contact us for more information (vc@biotroy.cn).
